Your browser doesn't support javascript.
loading
Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Lehtinen, Matti; Luostarinen, Tapio; Vänskä, Simopekka; Söderlund-Strand, Anna; Eriksson, Tiina; Natunen, Kari; Apter, Dan; Baussano, Iacopo; Harjula, Katja; Hokkanen, Mari; Kuortti, Marjo; Palmroth, Johanna; Petäjä, Tiina; Pukkala, Eero; Rekonen, Sirpa; Siitari-Mattila, Mari; Surcel, Heljä-Marja; Tuomivaara, Leena; Paavonen, Jorma; Nieminen, Pekka; Dillner, Joakim; Dubin, Gary; Garnett, Geoff.
Afiliación
  • Lehtinen M; Department of Laboratory Medicine, Karolinska Institute, Huddinge, Sweden.
  • Luostarinen T; Department of Laboratory Medicine, Karolinska Institute, Huddinge, Sweden.
  • Vänskä S; Helsinki and Oulu, Institute for Health and Welfare, Helsinki, Finland.
  • Söderlund-Strand A; Department of Clinical Microbiology, Skåne University hospital, Lund, Sweden.
  • Eriksson T; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Natunen K; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Apter D; VL Medi, Helsinki, Finland.
  • Baussano I; Department of Infections and Cancer, International Agency for Research on Cancer, Lyon, France.
  • Harjula K; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Hokkanen M; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Kuortti M; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Palmroth J; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Petäjä T; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Pukkala E; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Rekonen S; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Siitari-Mattila M; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Surcel HM; Department of Clinical Microbiology, Skåne University hospital, Lund, Sweden.
  • Tuomivaara L; School of Health Sciences, University of Tampere, Tampere, Finland.
  • Paavonen J; Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland.
  • Nieminen P; Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland.
  • Dillner J; Department of Laboratory Medicine, Karolinska Institute, Huddinge, Sweden.
  • Dubin G; Takeda Pharmaceuticals International, Zurich, Switzerland.
  • Garnett G; Gates Foundation, Seattle, Washington.
Int J Cancer ; 143(9): 2299-2310, 2018 11 01.
Article en En | MEDLINE | ID: mdl-29845626
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Papillomaviridae / Infecciones por Papillomavirus / Inmunidad Colectiva / Vacunas contra Papillomavirus Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Límite: Adolescent / Child / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Int J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Papillomaviridae / Infecciones por Papillomavirus / Inmunidad Colectiva / Vacunas contra Papillomavirus Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Límite: Adolescent / Child / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Int J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos